Tuberculosis remains one of humanity's most persistent killers, yet the pace of progress toward elimination targets is now seriously in question — not because the science has failed, but because funding cuts and structural gaps may undo decades of hard-won gains. Understanding exactly where the burden stood before these disruptions is now a critical baseline for global health planning.
This landmark GBD 2023 systematic analysis, covering 204 countries and territories from 1990 through 2023, offers the most comprehensive picture yet of TB's evolving burden across HIV status and drug-resistance profiles. Using an ensemble cause-of-death modeling approach integrated with vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data, researchers estimated that global TB mortality declined approximately 38% over the study period — meaningful progress, but well short of the WHO End TB Strategy's target of a 95% reduction in deaths by 2035. Incidence reductions have similarly lagged. Multidrug-resistant TB (MDR-TB) was specifically stratified using population attributable fractions, revealing its disproportionate contribution to years of life lost in high-burden regions. HIV-associated TB was modeled as a distinct stratum, underscoring the compounding mortality risk when both infections co-occur. Key modifiable risk factors quantified include alcohol use, smoking, and elevated fasting plasma glucose — highlighting that TB vulnerability is partially a metabolic and behavioral story, not solely a poverty or exposure story.
This analysis is paradigm-relevant rather than paradigm-shifting: it confirms known trends at unprecedented resolution across 34 years and 204 geographies. Its greatest value lies in establishing a pre-disruption baseline, since recent contractions in global health financing — particularly affecting high-burden low-income countries — threaten to reverse incidence and mortality trajectories. The MDR-TB findings deserve particular attention; drug-resistant strains are largely invisible in routine vital statistics and require exactly the kind of multi-source modeling used here. For health-conscious adults in high-income countries, the risk is indirect but real — MDR-TB respects no borders, and reductions in global control capacity historically translate into importation risk and reduced antibiotic efficacy pipelines.